Basiliximab, Tacrolimus, MMF, Prednisolon + Basiliximab, Tacrolimus, MMF + Tacrolimus, MMF, rATG
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Disorder Related to Renal Transplantation
Conditions
Disorder Related to Renal Transplantation
Trial Timeline
Jun 1, 2008 → Jul 1, 2014
NCT ID
NCT00724022About Basiliximab, Tacrolimus, MMF, Prednisolon + Basiliximab, Tacrolimus, MMF + Tacrolimus, MMF, rATG
Basiliximab, Tacrolimus, MMF, Prednisolon + Basiliximab, Tacrolimus, MMF + Tacrolimus, MMF, rATG is a approved stage product being developed by Astellas Pharma for Disorder Related to Renal Transplantation. The current trial status is completed. This product is registered under clinical trial identifier NCT00724022. Target conditions include Disorder Related to Renal Transplantation.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00724022 | Approved | Completed |
Competing Products
20 competing products in Disorder Related to Renal Transplantation
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Duloxetine + venlafaxine + placebo | Eli Lilly | Phase 3 | 77 |
| Ketamine + Placebo | Roivant Sciences | Phase 1 | 30 |
| duloxetine | Eli Lilly | Pre-clinical | 23 |
| SUBLOCADE | Indivior PLC | Phase 3 | 72 |
| SUBLOCADE | Indivior PLC | Phase 3 | 72 |
| TSHA-101 | Taysha Gene Therapies | Phase 1/2 | 36 |
| Olanzapine | Eli Lilly | Phase 3 | 77 |
| Valproate + Lithium + Risperidone + Olanzapine | Eli Lilly | Phase 3 | 77 |
| Olanzapine + Placebo | Eli Lilly | Approved | 85 |
| Duloxetine Hydrochloride | Eli Lilly | Pre-clinical | 23 |
| LY2216684 | Eli Lilly | Phase 1 | 33 |
| ACT-541468 5 mg + ACT-541468 10 mg + ACT-541468 25 mg + Zolpidem + Placebo 1 + Placebo 2 | Idorsia | Phase 2 | 47 |
| LY2216684 | Eli Lilly | Phase 1 | 33 |
| atomoxetine | Eli Lilly | Approved | 85 |
| Atomoxetine + Placebo | Eli Lilly | Phase 2/3 | 65 |
| LY2422347 + placebo | Eli Lilly | Phase 2 | 52 |
| Low Dose REN001 + High Dose REN001 | OnKure Therapeutics | Phase 1 | 25 |
| Atomoxetine | Eli Lilly | Approved | 85 |
| Duloxetine | Eli Lilly | Phase 3 | 77 |
| Duloxetine (Cymbalta) | Eli Lilly | Approved | 85 |